Novartis won European approval for its gene therapy Zolgensma for the hereditary disease spinal muscular atrophy (SMA), the Swiss drugmaker said on Tuesday, adding it is in talks over price with countries in hopes of a quick launch. ......
Full ArticleNovartis wins conditional EU approval for gene therapy Zolgensma
WorldNews
0 shares
1 views
You might like
Related news coverage
Novartis wins conditional European approval for gene therapy Zolgensma
Swiss drugmaker Novartis said on Tuesday it was awarded conditional European approval for its gene therapy Zolgensma for treating..
Reuters India